196 related articles for article (PubMed ID: 11190861)
1. [Estimation of the prevalence of Parkinson's disease in Asturia, Spain. A pharmacoepidemiological study of the consumption of antiparkinson drugs].
Martínez-Suárez MM; Blázquez-Menes B
Rev Neurol; 2000 Dec 1-15; 31(11):1001-6. PubMed ID: 11190861
[TBL] [Abstract][Full Text] [Related]
2. [Use of antiparkinsonian agents in Castilla-La Mancha. Estimate of prevalence of Parkinson disease].
Criado-Alvarez JJ; Romo-Barrientos C; Martínez-Hernández J; González-Solana I
Rev Neurol; 1998 Sep; 27(157):405-8. PubMed ID: 9774809
[TBL] [Abstract][Full Text] [Related]
3. [The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti-parkinsonian drugs].
Artázcoz Sanz MT; Viñes Rueda JJ
Rev Esp Salud Publica; 1995; 69(6):479-85. PubMed ID: 8789360
[TBL] [Abstract][Full Text] [Related]
4. [The prevalence and pharmacological cost of Parkinson's disease in Spain].
Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T
Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323
[TBL] [Abstract][Full Text] [Related]
5. A pharmacoepidemiological study of the consumption of antiparkinson drugs in the Basque Autonomous Community (Spain) (1992-2004).
Osinaga EA; Inchaurregui LC; Ikobaltzeta IE; Alonso NB; Del Pozo JG
Parkinsonism Relat Disord; 2007 Dec; 13(8):500-4. PubMed ID: 17532251
[TBL] [Abstract][Full Text] [Related]
6. [The evolution of use of anti-Parkinson drugs in Spain].
Montané E; Vallano Ferraz A; Castel JM
Rev Neurol; 2002 Apr 1-15; 34(7):612-7. PubMed ID: 12080509
[TBL] [Abstract][Full Text] [Related]
7. Population prevalence and incidence of Parkinson's disease in an Australian community.
Mehta P; Kifley A; Wang JJ; Rochtchina E; Mitchell P; Sue CM
Intern Med J; 2007 Dec; 37(12):812-4. PubMed ID: 17561942
[TBL] [Abstract][Full Text] [Related]
8. Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study.
Brandt-Christensen M; Kvist K; Nilsson FM; Andersen PK; Kessing LV
Mov Disord; 2006 Aug; 21(8):1221-5. PubMed ID: 16671076
[TBL] [Abstract][Full Text] [Related]
9. Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records.
van de Vijver DA; Roos RA; Jansen PA; Porsius AJ; de Boer A
Pharmacoepidemiol Drug Saf; 2001; 10(6):549-54. PubMed ID: 11828838
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Parkinson's disease in Spain.
Grandas F; Kulisevsky J
Mov Disord; 2003 Jan; 18(1):87-9. PubMed ID: 12518304
[TBL] [Abstract][Full Text] [Related]
11. [Daily defined doses of parkinsonian drugs in Alcoi].
Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C
Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
[TBL] [Abstract][Full Text] [Related]
12. [Estimate of type I bipolar disorder prevalence (1996-1998)].
Criado-Alvarez JJ; Domper Tornil JA; de la Rosa Rodríguez G
Rev Esp Salud Publica; 2000; 74(2):131-8. PubMed ID: 10918804
[TBL] [Abstract][Full Text] [Related]
13. Punding prevalence in Parkinson's disease.
Miyasaki JM; Al Hassan K; Lang AE; Voon V
Mov Disord; 2007 Jun; 22(8):1179-81. PubMed ID: 17230464
[TBL] [Abstract][Full Text] [Related]
14. [Drug consumption in diabetes mellitus (I). Estimate of the therapeutic profile and the prevalence in the regions of Tarragona (548,900 inhabitants). Grup per a l'Estudi de la Diabetis a Tarragona].
Costa B; Utgés P; Monclús JF; Gomis T; Ciurana MR; Julve P
Med Clin (Barc); 1992 Sep; 99(8):294-9. PubMed ID: 1453822
[TBL] [Abstract][Full Text] [Related]
15. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset.
Diederich NJ; Moore CG; Leurgans SE; Chmura TA; Goetz CG
Arch Neurol; 2003 Apr; 60(4):529-33. PubMed ID: 12707066
[TBL] [Abstract][Full Text] [Related]
16. Ongoing challenges to finding people with Parkinson's disease for epidemiological studies: a comparison of population-level case ascertainment methods.
Harris MA; Koehoorn M; Teschke K
Parkinsonism Relat Disord; 2011 Jul; 17(6):464-9. PubMed ID: 21531606
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
18. Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population.
Brefel-Courbon C; Grolleau S; Thalamas C; Bourrel R; Allaria-Lapierre V; Loï R; Micallef-Roll J; Lapeyre-Mestre M
Pain; 2009 Jan; 141(1-2):14-8. PubMed ID: 19062167
[TBL] [Abstract][Full Text] [Related]
19. Adherence to antiparkinson medication in a multicenter European study.
Grosset D; Antonini A; Canesi M; Pezzoli G; Lees A; Shaw K; Cubo E; Martinez-Martin P; Rascol O; Negre-Pages L; Senard A; Schwarz J; Strecker K; Reichmann H; Storch A; Löhle M; Stocchi F; Grosset K
Mov Disord; 2009 Apr; 24(6):826-32. PubMed ID: 19191340
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of Parkinson's disease in an area of North Tyneside in the North-East of England.
Porter B; Macfarlane R; Unwin N; Walker R
Neuroepidemiology; 2006; 26(3):156-61. PubMed ID: 16493203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
